Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bacolod, M. D.
Right arrow Articles by Friedman, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacolod, M. D.
Right arrow Articles by Friedman, H. S.
Vol. 1, 727-736, July 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Mechanisms of Resistance to 1,3-Bis(2-chloroethyl)-1-nitrosourea in Human Medulloblastoma and Rhabdomyosarcoma1

Manny D. Bacolod, Stewart P. Johnson, Francis Ali-Osman, Paul Modrich, Nancy S. Bullock, O. Michael Colvin, Darell D. Bigner and Henry S. Friedman2

Departments of Surgery [H.S.F., M.D.B., S.P.J., N.S.B.], Pediatrics [H.S.F.], Pathology [H.S.F., D.D.B.], Medicine [H.S.F., O.M.C.], and Biochemistry [P.M.] and The Howard Hughes Medical Institute [P.M.], Duke University Medical Center, Durham, NC 27710, and Department of Neurosurgery, MD Anderson Cancer Center, Houston, Texas 77030 [F.A-O.]

Medulloblastoma (D-341 MED) and rhabdomyosarcoma (TE-671) cell lines, which are resistant to either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of BCNU and O6-benzylguanine (O6-BG), were generated by serial escalation of BCNU. The activities of O6-alkylguanine-DNA alkyltransferase (AGT), glutathione-S-transferase (GST), and total glutathione (GSH) of the parental, BCNU-resistant (BR), and BCNU + O6-BG-resistant (OBR) cells were measured. No significant differences in GST activity or total GSH were seen between the parental, BR, and OBR cells of both TE-671 and D-341 MED. The AGT activities of D-341 MED (BR) and TE-671 (BR) were twice those of D-341 MED and TE-671, respectively, confirming the importance of this enzyme for BCNU resistance. The D-341 MED (OBR) cells did not exhibit any AGT activity, suggesting that another mechanism must play a role in the drug resistance. Fewer DNA interstrand cross-links (ICLs) were observed in D-341 MED (OBR) than in D-341 MED after 8 h BCNU (100–400 µM) treatment. However, the amounts of DNA ICLs observed in D-341 MED and D-341 MED (OBR) were stable after 24 h. Microarray analysis showed the increased expressions of several metallothionein genes and down-regulation of several proapoptotic genes. The AGT activity of TE-671 (OBR) was 223 fmol/mg when the cells were grown in 10 µM O6-BG and decreased to about half this value when the O6-BG concentration was increased 60 µM. The AGT cDNA of TE-671 (OBR) cells was cloned and found to contain a G-to-T transversion at codon 156, resulting in conversion of glycine to cysteine (G156C). In vitro mutagenesis has shown that the G156C AGT mutant is resistant to inactivation by O6-BG. Thus, the selection of a mutant AGT with decreased sensitivity to O6-BG is a significant contributing factor to BCNU + O6-BG resistance.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. A. Maxwell, S. P. Johnson, R. E. McLendon, D. W. Lister, K. S. Horne, A. Rasheed, J. A. Quinn, F. Ali-Osman, A. H. Friedman, P. L. Modrich, et al.
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
Clin. Cancer Res., August 1, 2008; 14(15): 4859 - 4868.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. D. Bacolod, S. P. Johnson, A. E. Pegg, M. E. Dolan, R. C. Moschel, N. S. Bullock, Q. Fang, O. M. Colvin, P. Modrich, D. D. Bigner, et al.
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
Mol. Cancer Ther., September 1, 2004; 3(9): 1127 - 1135.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, F. Kokocinski, A. Golanov, S. Joos, and P. Lichter
Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival
Cancer Res., May 1, 2004; 64(9): 3103 - 3111.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.